NASDAQ:APLT Applied Therapeutics (APLT) Stock Price, News & Analysis $0.45 +0.01 (+1.77%) As of 03:33 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Applied Therapeutics Stock (NASDAQ:APLT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Applied Therapeutics alerts:Sign Up Key Stats Today's Range$0.43▼$0.4650-Day Range$0.34▼$0.5452-Week Range$0.30▼$10.62Volume566,226 shsAverage Volume2.47 million shsMarket Capitalization$64.52 millionP/E RatioN/ADividend YieldN/APrice Target$6.10Consensus RatingModerate Buy Company Overview Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel small-molecule therapies for genetically defined diseases. Its research strategy centers on structure-based drug design and proprietary screening technologies aimed at correcting underlying metabolic dysfunction in disorders characterized by enzyme deficiencies and toxic metabolite accumulation. The company’s lead investigational candidate, AT-007, is an aldose reductase inhibitor engineered to cross the blood–brain barrier and is currently in clinical development for classic galactosemia. In addition to AT-007, Applied Therapeutics is advancing multiple programs targeting rare neurological and endocrine disorders, leveraging its platform to identify and optimize compounds that address high unmet medical needs in orphan and genetically defined patient populations. Founded and headquartered in New York City, Applied Therapeutics has established collaborative partnerships with academic research institutions and contract research organizations throughout North America and Europe to support its preclinical and clinical operations. The company is guided by a leadership team with extensive experience in drug discovery, clinical development and regulatory affairs, positioning Applied Therapeutics to advance its pipeline toward key clinical milestones and potential regulatory approval.AI Generated. May Contain Errors. Read More Applied Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks75th Percentile Overall ScoreAPLT MarketRank™: Applied Therapeutics scored higher than 75% of companies evaluated by MarketBeat, and ranked 250th out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingApplied Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.Upside PotentialApplied Therapeutics has a consensus price target of $6.10, representing about 1,264.7% upside from its current price of $0.45.Amount of Analyst CoverageApplied Therapeutics has received no research coverage in the past 90 days.Read more about Applied Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Applied Therapeutics are expected to grow in the coming year, from ($0.65) to ($0.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Applied Therapeutics is -1.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Applied Therapeutics is -1.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioApplied Therapeutics has a P/B Ratio of 0.91. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Applied Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted6.10% of the outstanding shares of Applied Therapeutics have been sold short.Short Interest Ratio / Days to CoverApplied Therapeutics has a short interest ratio ("days to cover") of 5.4.Change versus previous monthShort interest in Applied Therapeutics has recently decreased by 10.22%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldApplied Therapeutics does not currently pay a dividend.Dividend GrowthApplied Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.88 Percentage of Shares Shorted6.10% of the outstanding shares of Applied Therapeutics have been sold short.Short Interest Ratio / Days to CoverApplied Therapeutics has a short interest ratio ("days to cover") of 5.4.Change versus previous monthShort interest in Applied Therapeutics has recently decreased by 10.22%, indicating that investor sentiment is improving significantly. News and Social Media0.0 / 5News SentimentN/A Search InterestOnly 3 people have searched for APLT on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Applied Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Applied Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.60% of the stock of Applied Therapeutics is held by insiders.Percentage Held by Institutions98.31% of the stock of Applied Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Applied Therapeutics' insider trading history. Receive APLT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Applied Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. APLT Stock News HeadlinesApplied Therapeutics Reports Q2 LossAugust 15, 2025 | theglobeandmail.comApplied Therapeutics reports Q2 EPS (15c), consensus (16c)August 14, 2025 | msn.comThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profitable trends in tech … well ahead of Wall Street. Like when he called Nvidia at a mere 80 cents a share. Or Bitcoin when it was trading for just $300. Throughout his illustrious career … Michael has given his followers almost 150 different chances to register triple-digit gains.September 10 at 2:00 AM | Weiss Ratings (Ad)Applied Therapeutics Reports Second Quarter 2025 Financial ResultsAugust 13, 2025 | globenewswire.comApplied Therapeutics, Inc. (APLT) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comApplied Therapeutics Announces Key Leadership AppointmentsJune 17, 2025 | globenewswire.comApplied announces INSPIRE Phase 2/3 trial primary endpoint not significantMay 18, 2025 | msn.comApplied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual MeetingMay 18, 2025 | globenewswire.comSee More Headlines APLT Stock Analysis - Frequently Asked Questions How have APLT shares performed this year? Applied Therapeutics' stock was trading at $0.8562 on January 1st, 2025. Since then, APLT shares have decreased by 47.8% and is now trading at $0.4470. How were Applied Therapeutics' earnings last quarter? Applied Therapeutics Inc. (NASDAQ:APLT) issued its quarterly earnings data on Wednesday, August, 13th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.02. When did Applied Therapeutics IPO? Applied Therapeutics (APLT) raised $60 million in an IPO on the week of May 13th 2019. The company issued 4,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and UBS Investment Bank acted as the underwriters for the IPO and Baird was co-manager. Who are Applied Therapeutics' major shareholders? Applied Therapeutics' top institutional investors include Qube Research & Technologies Ltd (1.29%), Marshall Wace LLP (1.09%), Adage Capital Partners GP L.L.C. (0.86%) and Geode Capital Management LLC (0.68%). Insiders that own company stock include Real Estate Equitie Alexandria, Shoshana Shendelman, Riccardo Perfetti, Leslie D Funtleyder and Stacy J Kanter. View institutional ownership trends. How do I buy shares of Applied Therapeutics? Shares of APLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Applied Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Applied Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), Advanced Micro Devices (AMD) and ServiceNow (NOW). Company Calendar Last Earnings8/13/2025Today9/10/2025Next Earnings (Estimated)11/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:APLT CIK1697532 Webwww.appliedtherapeutics.com Phone(212) 220-9226FaxN/AEmployees30Year Founded2017Price Target and Rating Average Price Target for Applied Therapeutics$6.10 High Price Target$14.00 Low Price Target$1.50 Potential Upside/Downside+1,264.7%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$105.62 million Net MarginsN/A Pretax Margin-55,523.77% Return on Equity-354.24% Return on Assets-144.16% Debt Debt-to-Equity RatioN/A Current Ratio1.94 Quick Ratio1.94 Sales & Book Value Annual Sales$121 thousand Price / Sales532.01 Cash FlowN/A Price / Cash FlowN/A Book Value$0.49 per share Price / Book0.91Miscellaneous Outstanding Shares144,012,000Free Float141,708,000Market Cap$64.37 million OptionableOptionable Beta2.05 Social Links 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:APLT) was last updated on 9/10/2025 by MarketBeat.com Staff From Our PartnersWorld War 3? Everything Just Changed — and One Tiny Company Is at the Center of It.Trump immediately activated a $5.3 TRILLION AI missile shield — code-named Golden Dome — to stop drone swarms ...Angel Publishing | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredWall Street legend: “Put $1,000 in this AI stock”A massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | Sponsored“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Applied Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Applied Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.